Perrigo, a provider of Consumer Self-Care Products, announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC). Perrigo expects to launch Omeprazole Minis later this year.

This launch represents a first-to-market mini capsule form of omeprazole, which is indicated for the treatment of frequent heartburn. This capsule is 70% smaller than the tablet version of omeprazole that is currently available, providing a differentiated and preferred product offering for consumers. The product will be marketed under the retailer's store brand labels comparable to Prilosec OTC.

Perrigo Executive Vice President & President, Consumer Self-Care Americas, Jim Dillard commented, "This approval illustrates Perrigo's research and development and regulatory expertise and our continued focus on product innovation to provide value for both our customers and consumers. The omeprazole mini product exemplifies our national-brand-different strategy and provides our store brand partners with a differentiated product in the marketplace."